Description
Medical Uses of mobocertinib capsules
Mobocertinib is indicated for adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy.
Mobocertinib, is used for the treatment of non-small cell lung cancer. Mobocertinib is a small molecule tyrosine kinase inhibitor. Its molecular target is epidermal growth factor receptor (EGFR) bearing mutations in the exon 20 region. Mobocertinib is an irreversible kinase inhibitor, forming a covalent bond with the cysteine 797 in the EGFR active site, leading to sustained inhibition of EGFR enzymatic activity. The irreversible binding leads to increased potency via higher affinity binding, more sustained EGFR kinase activity inhibition, and greater overall selectivity, as only a limited number of other kinases possess a cysteine in the equivalent position.
Mobocertinib was approved for medical use in the United States in September 2021. It is a first-in-class oral treatment to target EGFR Exon20 insertion mutations.
Get Access To EXKIVITY (mobocertinib) capsules In India
Brand Name “EXKIVITY (mobocertinib) capsules” or Generic Name “mobocertinib capsules” can be imported for personal use under “Named Patient Program” treatment in Delhi, Mumbai, Kolkata, Chennai, Bangalore, Hyderabad, Ahmedabad, Pune, Surat, Jaipur, Coimbatore, Noida, Gurgaon, Punjab, Chandigarh, Bhubaneswar, Arunachal Pradesh, Assam, Manipur, Meghalaya, Mizoram, Nagaland, Tripura and Sikkim, India. Contact us at support@southdelhipharma.com, southdelhipharma@gmail.com or call/WhatsApp at +91-9891296838 to get access as per norms.
Pharma Services and Drug Inquiries
Our Pharma Division deals only with the best, GMP certified generics and branded medication for the export market. All our products are supported by strict adherence to quality and analysis certification.
Please note for the minimum order for Exports is of US$ 300. All orders will be subject to courier charges and supplies are normally dispatched through internationally accredited courier services.
Complete the form below to receive the no-obligation price quote.
Disclaimer
Note : We do not supply schedule-H (Example – narcotic drug or psychotropic drugs or anabolic steroids) and Anti- Abortion Drugs.
All Trademarks and Brands that appear on the website belong to their respective owners and South Delhi Pharma does not lay any claim on them we only provide Information. Following Information meant for Wholesalers, Suppliers, Exporters, Doctors, Comparator Supplies, Hospitals, Generic, Brand, Corporate Sourcing, reseller, and Pharmacies.
Global Network
South Delhi Pharma, Delhi India is a leading Pharmaceutical Distributor / Supplier / Exporter / Importer of Specialty Pharmaceutical drugs. Having more than 25 years of experience. Supplying innovator and generic anti cancer products at the most competitive prices. Contact us at support@southdelhipharma.com, southdelhipharma@gmail.com or call/WhatsApp at +91-9891296838 to get access as per norms.
Get Access In India
Delhi, Mumbai, Kolkata, Chennai, Bangalore, Hyderabad, Ahmedabad, Pune, Surat, Jaipur, Coimbatore, Noida, Gurgaon, Punjab, Chandigarh, Bhubaneswar, Arunachal Pradesh, Assam, Manipur, Meghalaya, Mizoram, Nagaland, Tripura and Sikkim, India.
Get Access In Overseas
Besides India, we have been able to cater medicines request coming from East Asia – China (Beijing, Chongqing, Shanghai, Tianjin and Shenzhen), Cambodia, Indonesia, Malaysia, the Philippines, Singapore, Thailand, Vietnam, Hong Kong. United Arab Emirates – Iraq, Iran, Saudi Arabia, Jordan. North America – Mexico. South America – Argentina, Brazil, Chile, Colombia, Peru, Venezuela. Europe – Romania, Switzerland, Georgia, Turkey, Italy, UK, Ukraine, Azerbaijan, Latvia, Poland, Slovakia. Russia CIS – Armenia, Kazakhstan, Moldova, Tajikistan, Turkmenistan, Uzbekistan, Mongolia. African Countries – Algeria, Mauritius, Uganda, Zimbabwe. Australia and New Zealand. Europe, USA, China, Australia, ASEAN countries and Latin American countries.
